iRhythm sees FY26 revenue $870M-$880M, consensus $862.68M

For full year 2026, expect revenue of approximately $870 million to $880 million, or approximately 17% to 18% year-over-year growth, and anticipate adjusted EBITDA margin of approximately 11.5% to 12.5%. “2025 has been a transformative year for iRhythm (IRTC), with strong execution against our aspiration to drive best-in-class quality systems, record commercial volumes, over 25% year-over-year revenue growth, and achieving free cash flow positivity for the first time in company history,” said Quentin Blackford, iRhythm’s President and CEO. “Our comprehensive clinical evidence program – including AVALON and CAMELOT publications – continues to reinforce Zio LTCM’s clinical superiority in support of addressable market expansion across additional populations and care settings. As we enter 2026, we’re well-positioned to accelerate our leadership with multiple growth catalysts ahead, including deepening penetration in primary care and population health through AI-powered risk stratification partnerships, momentum within mobile cardiac telemetry, expansion into adjacent markets such as obstructive sleep apnea, and continued international execution. With our proven ability to scale efficiently, we’re confident we can deliver sustainable, profitable growth while transforming cardiac care for millions of patients worldwide.”

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential